Condition
NK-T-Cell Lymphoma, Extranodal
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Unknown1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06069830Not ApplicableRecruitingPrimary
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
NCT06953739Phase 3Not Yet RecruitingPrimary
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
NCT05774028Phase 2UnknownPrimary
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma
Showing all 3 trials